Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efonidipine SCHEMBL29410289 | 1.00 | ABCB1 (1.00) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL29379054 | 1.00 | ABCB1 (1.00) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL49638 | 1.00 | ABCB1 (1.00) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL349046 | 0.99 | ABCB1 (0.99) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL332377 | 0.99 | ABCB1 (0.99) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL678571 | 0.99 | ABCB1 (0.97) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL28844127 | 0.99 | ABCB1 (0.97) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL27650540 | 0.98 | ABCB1 (0.96) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL909287 | 0.97 | ABCB1 (0.95) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL909286 | 0.97 | ABCB1 (0.95) | ABCB1CACNA1CCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7210 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4529461-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-02 | — | — | EP | claimed |
| CN-119633109-A | Application of efonidipine in preparation of dendritic cell immunoadjuvant | 中国人民解放军军事科学院军事医学研究院 | 2025-03-18 | — | — | CN | claimed |
| CN-119255805-A | Can be used for treating hypertension Alpraxitanum of (C) | 爱杜西亚药品有限公司 | 2025-01-03 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| JP-3352095-B2 | — | — | 2002-12-03 | — | — | JP | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002060461-A1 | BLOOD BRAIN BARRIER MODULATION USING STRESSED AUTOLOGOUS BLOOD CELLS | VASOGEN IRELAND LIMITED (IE) | 2002-08-08 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| JP-2001517210-A | — | — | 2001-10-02 | — | — | JP | claimed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | claimed |
| CN-1248162-A | Topical pharmaceutical composition containing cholinergic agent or calcium channel blocker | MICHAEL ALBERT KAMM (GB) | 2000-03-22 | — | — | CN | claimed |
| EP-0969813-A2 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER | Kamm, Michael Albert (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
| WO-1998036733-A2 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER | KAMM MICHAEL ALBERT (GB) | 1998-08-27 | — | — | WO | claimed |